LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 19

Search options

  1. Article: Pursuing clinician investigator programs in residency.

    Bidnur, Samir

    Canadian Urological Association journal = Journal de l'Association des urologues du Canada

    2016  Volume 10, Issue 5-6, Page(s) 215

    Language English
    Publishing date 2016-08-01
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 2431403-1
    ISSN 1911-6470
    ISSN 1911-6470
    DOI 10.5489/cuaj.3890
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: The CUA-AUA International Fellows Exchange Program: New Orleans 2015.

    Bidnur, Samir

    Canadian Urological Association journal = Journal de l'Association des urologues du Canada

    2011  Volume 9, Issue 7-8, Page(s) 283

    Language English
    Publishing date 2011-05-15
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 2431403-1
    ISSN 1911-6470
    ISSN 1911-6470
    DOI 10.5489/cuaj.3232
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Mediators of human ureteral smooth muscle contraction-a role for erythropoietin, tamsulosin and Gli effectors.

    Scotland, Kymora B / Bidnur, Samir / Wang, Lu / Chew, Ben H / Lange, Dirk

    Translational andrology and urology

    2021  Volume 10, Issue 7, Page(s) 2953–2961

    Abstract: Background: Ureteral contractility is a poorly understood process. Contractions have been demonstrated to occur in the smooth muscle layers of the ureter. Previous work suggests the involvement of Gli family proteins and erythropoietin (EPO) in ... ...

    Abstract Background: Ureteral contractility is a poorly understood process. Contractions have been demonstrated to occur in the smooth muscle layers of the ureter. Previous work suggests the involvement of Gli family proteins and erythropoietin (EPO) in regulating mammalian ureteral smooth muscle contraction. We sought to devise a method by which the effects of these proteins and tamsulosin on distal human ureteral tissue contractility could be investigated to better understand mechanisms regulating human ureteral function.
    Methods: IRB approval was obtained to procure portions of extraneous distal ureteral tissue from living donor renal transplants. Contractility was measured by placing the tissue in Krebs buffer and stimulating via a uniform electric current. Contractile force was recorded with each stimulation with and without the presence of a Gli inhibitor (GANT61) or EPO. Each ureteral specimen was subsequently fixed and tested by immunohistochemistry to determine Gli, EPO and alpha-adrenergic receptor activity.
    Results: Electrical field stimulation successfully elicited contractions in the ureteral tissue. Administering tamsulosin decreased force and duration of ureteral contractions. Inhibiting Gli signaling decreased contractility and EPO decreased ureteral contractile forces within 5 minutes of administration versus untreated controls. Staining confirmed Gli1 protein and α-adrenergic receptor expression in ureteral smooth muscle and epithelial tissue with EPO receptor expression confined to the epithelial layer.
    Conclusions: Distal ureteral contractile forces are decreased by inhibition of Gli family proteins and the α-adrenergic receptor. EPO acts within five minutes, suggesting ion channel involvement instead of changes in gene expression. Continuing work will elucidate the role of these proteins in coordinating ureteral contractions. This has implications for the use of pharmacologic methods to address ureteral contractility and dysfunctional peristalsis during stone passage, ureteroscopy, in transplant patients and potentially to reduce symptoms from ureteral stents.
    Language English
    Publishing date 2021-08-06
    Publishing country China
    Document type Journal Article
    ZDB-ID 2851630-8
    ISSN 2223-4691 ; 2223-4691 ; 2223-4683
    ISSN (online) 2223-4691
    ISSN 2223-4691 ; 2223-4683
    DOI 10.21037/tau-20-1342
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer.

    Bidnur, S / Savdie, R / Black, P C

    Bladder cancer (Amsterdam, Netherlands)

    2016  Volume 2, Issue 1, Page(s) 15–25

    Abstract: ... cell activation and immune-mediated anti-tumour activity- essentially harnessing the patient's own ...

    Abstract Background: Increasing evidence supporting the role of immune checkpoint blockade in cancer management has been bolstered by recent reports demonstrating significant and durable clinical responses across multiple tumour types, including metastatic urothelial carcinoma (mUC). The majority of these results are achieved via blockade of the programmed death (PD) axis, which like CTLA-4 blockade permits T-cell activation and immune-mediated anti-tumour activity- essentially harnessing the patient's own immune system to mount an anti-neoplastic response. However, while clinical responses can be striking, our understanding of the biology of immune checkpoint blockade is only beginning to shed light on how to maximize and even improve patient outcomes with immune checkpoint blockade, especially in UC.
    Methods: We performed a literature review for immune checkpoint blockade with a focus on rationale for checkpoint therapy and outcomes in UC. We also highlight the advances made in other tumour types, with a focus on the recent 2015 meeting of the American Society for Clinical Oncology.
    Results: In heavily pre-treated UC, trials are suggesting objective response rates above 30% . These impressive results are seen across multiple different tumour types, especially those with high burden of DNA level mutations. Identification of prognostic biomarkers is currently under investigation, in order to improve patient selection. Interestingly, response to PD-1 directed therapy is seen even in patients with no evidence of PD-1 positivity on immunohistochemistry. This has led to the development of enhanced biomarkers including assessing DNA mutation rates and immune gene signatures, to improve patient selection.
    Conclusions: Immune checkpoint blockade is an exciting cancer treatment modality which is demonstrating impressive clinical results across multiple tumour types. For UC, anti-PD directed therapy represents a much needed treatment in the metastatic, post chemotherapy context. Potential for these agents to have clinical utility in non-metastatic UC is still to be assessed.
    Language English
    Publishing date 2016-01-07
    Publishing country Netherlands
    Document type Review ; Journal Article
    ISSN 2352-3727
    ISSN 2352-3727
    DOI 10.3233/BLC-150026
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Case - Uretero-internal iliac artery fistula presenting with multiple negative angiographic studies.

    Sarwal, Gautamn / Bidnur, Samir / Chedgy, Edmund C P / Kavanagh, Alex

    Canadian Urological Association journal = Journal de l'Association des urologues du Canada

    2018  Volume 12, Issue 5, Page(s) E250–E252

    Language English
    Publishing date 2018-02-06
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 2431403-1
    ISSN 1911-6470
    ISSN 1911-6470
    DOI 10.5489/cuaj.4758
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: An Indwelling Ureteral Stent Forgotten for Over 12 Years.

    Bidnur, Samir / Huynh, Melissa / Hoag, Nathan / Chew, Ben

    Journal of endourology case reports

    2016  Volume 2, Issue 1, Page(s) 135–137

    Abstract: Ureteral stents are one of the most commonly used urologic devices with the purpose of establishing and maintaining ureteral patency. They are also associated with a number of complications including infection, migration, stent-related symptoms, and ... ...

    Abstract Ureteral stents are one of the most commonly used urologic devices with the purpose of establishing and maintaining ureteral patency. They are also associated with a number of complications including infection, migration, stent-related symptoms, and encrustation, leading to lithiasis. Prolonged stent dwell time is associated with a greater degree of these complications. We present the case of a 36-year-old man who presented with a severely encrusted ureteral stent that had been placed 12.5 years prior for an obstructive left-sided ureteral stone and was lost to follow-up. The patient underwent a combination of percutaneous nephrolithomy, cystolitholapaxy, and ureteroscopy to remove the stent and associated 1.7 cm renal pelvic stone and 4.1 cm bladder stone, necessitating two operative sittings to render him stone free.
    Language English
    Publishing date 2016-07-01
    Publishing country United States
    Document type Case Reports
    ISSN 2379-9889
    ISSN 2379-9889
    DOI 10.1089/cren.2016.0073
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Expanding Immunotherapy Options for Bladder Cancer: Commentary on: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

    Lavoie, Jean-Michel / Bidnur, Samir / Black, Peter C / Eigl, Bernhard J

    Urology

    2017  Volume 106, Page(s) 1–2

    MeSH term(s) Antibodies, Monoclonal, Humanized ; Carcinoma, Transitional Cell ; Humans ; Immunotherapy ; Urinary Bladder Neoplasms
    Chemical Substances Antibodies, Monoclonal, Humanized ; pembrolizumab (DPT0O3T46P)
    Language English
    Publishing date 2017-04-25
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 192062-5
    ISSN 1527-9995 ; 0090-4295
    ISSN (online) 1527-9995
    ISSN 0090-4295
    DOI 10.1016/j.urology.2017.04.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release.

    Schmitt, Veronika / Kesch, Claudia / Jackson, John K / Bidnur, Samir / Beraldi, Eliana / Yago, Virginia / Bowden, Mary / Gleave, Martin E

    Pharmaceutical research

    2020  Volume 37, Issue 3, Page(s) 36

    Abstract: Purpose: We describe the preparation of injectable polymeric paste (IPP) formulations for local and sustained release of drugs. Furthermore, we include the characterization and possible applications of such pastes. Particular attention is paid to ... ...

    Abstract Purpose: We describe the preparation of injectable polymeric paste (IPP) formulations for local and sustained release of drugs. Furthermore, we include the characterization and possible applications of such pastes. Particular attention is paid to characteristics relevant to the successful clinical formulation development, such as viscosity, injectability, degradation, drug release, sterilization, stability performance and pharmacokinetics.
    Methods: Paste injectability was characterized using measured viscosity and the Hagen-Poiseuille equation to determine injection forces. Drug degradation, release and formulation stability experiments were performed in vitro and drug levels were quantified using HPLC-UV methods. Pharmacokinetic evaluation of sustained-release lidocaine IPPs used five groups of six rats receiving increasing doses subcutaneously. An anti-cancer formulation was evaluated in a subcutaneous tumor xenograft mouse model.
    Results: The viscosity and injectability of IPPs could be controlled by changing the polymeric composition. IPPs demonstrated good long-term stability and tunable drug-release with low systemic exposure in vivo in rats. Preliminary data in a subcutaneous tumor model points to a sustained anticancer effect.
    Conclusions: These IPPs are tunable platforms for local and sustained delivery of drugs and have potential for further clinical development to treat a number of diseases.
    MeSH term(s) Anilides/chemistry ; Anilides/pharmacology ; Animals ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/therapeutic use ; Docetaxel/chemistry ; Docetaxel/pharmacology ; Drug Carriers/chemistry ; Drug Compounding/methods ; Drug Liberation ; Drug Stability ; Humans ; Injections ; Lidocaine/chemistry ; Lidocaine/pharmacokinetics ; Male ; Mice ; Mice, Nude ; Neoplasms, Experimental ; Nitriles/chemistry ; Nitriles/pharmacology ; Ointments/chemistry ; Polylactic Acid-Polyglycolic Acid Copolymer/chemistry ; Prostatic Neoplasms/drug therapy ; Rats ; Tosyl Compounds/chemistry ; Tosyl Compounds/pharmacology ; Viscosity
    Chemical Substances Anilides ; Antineoplastic Agents ; Drug Carriers ; Nitriles ; Ointments ; Tosyl Compounds ; Docetaxel (15H5577CQD) ; Polylactic Acid-Polyglycolic Acid Copolymer (1SIA8062RS) ; Lidocaine (98PI200987) ; bicalutamide (A0Z3NAU9DP)
    Language English
    Publishing date 2020-01-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 843063-9
    ISSN 1573-904X ; 0724-8741 ; 0739-0742
    ISSN (online) 1573-904X
    ISSN 0724-8741 ; 0739-0742
    DOI 10.1007/s11095-019-2730-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Late renal vein aneurysm following living related renal transplant.

    Dale, Robert T / Bidnur, Samir / Nguan, Christopher Y C

    Canadian Urological Association journal = Journal de l'Association des urologues du Canada

    2014  Volume 8, Issue 3-4, Page(s) E253–5

    Abstract: Renal vein aneurysms are rare; there are less than 10 reported cases. As of yet there have been no reported cases of renal vein aneurysm following renal transplantation. We present a case of an incidentally discovered renal vein aneurysm following ... ...

    Abstract Renal vein aneurysms are rare; there are less than 10 reported cases. As of yet there have been no reported cases of renal vein aneurysm following renal transplantation. We present a case of an incidentally discovered renal vein aneurysm following uncomplicated living related renal transplant. The lesion was discovered 4 years after the transplant through abdominal ultrasound investigation of new right lower quadrant discomfort. Magnetic resonance imaging confirmed the presence of a 2.3-cm thrombosed renal vein aneurysm of the main renal vein. This case report highlights the rare nature of these events, the diagnostic challenges and the lack of satisfactory management guidelines in these cases.
    Language English
    Publishing date 2014-04-28
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 2431403-1
    ISSN 1911-6470
    ISSN 1911-6470
    DOI 10.5489/cuaj.1769
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: PEG10 is associated with treatment-induced neuroendocrine prostate cancer.

    Kim, Soojin / Thaper, Daksh / Bidnur, Samir / Toren, Paul / Akamatsu, Shusuke / Bishop, Jennifer L / Colins, Colin / Vahid, Sepideh / Zoubeidi, Amina

    Journal of molecular endocrinology

    2019  Volume 63, Issue 1, Page(s) 39–49

    Abstract: Neuroendocrine (NE) differentiation of advanced prostate adenocarcinoma following androgen receptor (AR) axis-directed therapy is becoming increasingly recognized. Several models of this transdifferentiation provide insight into its molecular ... ...

    Abstract Neuroendocrine (NE) differentiation of advanced prostate adenocarcinoma following androgen receptor (AR) axis-directed therapy is becoming increasingly recognized. Several models of this transdifferentiation provide insight into its molecular pathogenesis and have highlighted the placental gene PEG10 for further study. Using our unique model of enzalutamide resistance (ENZR) and NE differentiation, we studied PEG10/AR interplay in enzalutamide treatment-resistant cell lines 42DENZR and 42FENZR compared to LNCaP and castration-resistant 16DCRPC cells. ENZR cell lines with positive terminal NE marker status also displayed higher baseline expression of PEG10 compared to LNCaP and 16DCRPC. Antagonism of AR activity increased PEG10 expression followed by an increase in terminal NE markers. Conversely, stimulating AR activity via androgen supplementation reversed PEG10 and NE marker expression in a time and dose-dependent manner. These results were supported by human data showing that PEG10 expression is highest in NEPC and that AR-dependent gene, PSA, is negatively correlated with PEG10 in adenocarcinoma. Further, ChIP assay confirmed binding of activated AR to the PEG10 enhancer, decreasing PEG10 expression. While PEG10 did not drive NEPC, its knockdown reduced NE markers in our cell lines. Moreover, PEG10 knockdown in vitro- and in vivo-attenuated tumor growth. Overall, these observations indicate that PEG10 is an AR-repressed gene which modulates NE markers in ENZR cells and targeting PEG10 in advanced prostate cancer with NE features is a rational and viable option.
    MeSH term(s) Animals ; Antineoplastic Agents/therapeutic use ; Apoptosis Regulatory Proteins/genetics ; Apoptosis Regulatory Proteins/metabolism ; Blotting, Western ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Chromatin Immunoprecipitation ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; Drug Resistance, Neoplasm/genetics ; Humans ; Male ; Mice ; Mice, Nude ; Neurosecretory Systems/metabolism ; Phenylthiohydantoin/analogs & derivatives ; Phenylthiohydantoin/therapeutic use ; Prostatic Neoplasms/chemically induced ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/metabolism ; RNA-Binding Proteins/genetics ; RNA-Binding Proteins/metabolism ; Receptors, Androgen/genetics ; Receptors, Androgen/metabolism ; Reverse Transcriptase Polymerase Chain Reaction ; Signal Transduction/genetics ; Signal Transduction/physiology
    Chemical Substances Antineoplastic Agents ; Apoptosis Regulatory Proteins ; DNA-Binding Proteins ; PEG10 protein, human ; RNA-Binding Proteins ; Receptors, Androgen ; Phenylthiohydantoin (2010-15-3) ; enzalutamide (93T0T9GKNU)
    Language English
    Publishing date 2019-04-19
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 645012-x
    ISSN 1479-6813 ; 0952-5041
    ISSN (online) 1479-6813
    ISSN 0952-5041
    DOI 10.1530/JME-18-0226
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top